| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones
|
Sturgeon, Christopher M.
|
|
2007
|
61 |
3 |
p. 407-413
|
article
|
| 2 |
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging
|
Bornmann, C.
|
|
2007
|
61 |
3 |
p. 395-405
|
article
|
| 3 |
A novel N-alkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type
|
Deorukhkar, Amit A.
|
|
2007
|
61 |
3 |
p. 355-363
|
article
|
| 4 |
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
|
Britten, Carolyn D.
|
|
2007
|
61 |
3 |
p. 515-524
|
article
|
| 5 |
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma
|
Jones, Robert J.
|
|
2007
|
61 |
3 |
p. 435-441
|
article
|
| 6 |
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
|
Ramanathan, Ramesh K.
|
|
2007
|
61 |
3 |
p. 453-458
|
article
|
| 7 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial
|
Yamamoto, Daigo
|
|
2007
|
61 |
3 |
p. 509-514
|
article
|
| 8 |
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells
|
Li, Jiannong
|
|
2007
|
61 |
3 |
p. 525-534
|
article
|
| 9 |
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide
|
Chung, Francisco
|
|
2007
|
61 |
3 |
p. 497-502
|
article
|
| 10 |
Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line
|
Sakayama, Kenshi
|
|
2007
|
61 |
3 |
p. 471-479
|
article
|
| 11 |
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
|
Bellott, Ricardo
|
|
2007
|
61 |
3 |
p. 481-488
|
article
|
| 12 |
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies
|
Evans, Andrew
|
|
2007
|
61 |
3 |
p. 377-393
|
article
|
| 13 |
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer
|
Royer, Bernard
|
|
2007
|
61 |
3 |
p. 415-421
|
article
|
| 14 |
Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance
|
Chen, Shuai
|
|
2007
|
61 |
3 |
p. 459-469
|
article
|
| 15 |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
|
Jimeno, Antonio
|
|
2007
|
61 |
3 |
p. 423-433
|
article
|
| 16 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
|
Yamamoto, Noboru
|
|
2007
|
61 |
3 |
p. 489-496
|
article
|
| 17 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
|
Yamamoto, Noboru
|
|
|
61 |
3 |
p. 489-496
|
article
|
| 18 |
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
|
Ohyanagi, Fumiyoshi
|
|
2007
|
61 |
3 |
p. 503-508
|
article
|
| 19 |
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
|
Kamath, Amrita V.
|
|
2007
|
61 |
3 |
p. 365-376
|
article
|
| 20 |
Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer
|
Saif, Muhammad Wasif
|
|
2007
|
61 |
3 |
p. 349-354
|
article
|
| 21 |
Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells
|
Fusi, Fabio
|
|
2007
|
61 |
3 |
p. 443-451
|
article
|
Journal description